Department Of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement Uniform Formulary Additional Discount Program

View Changes Background The Department Of Defense Dod Is Required By Law 10 U S C 1074G To Establish An Effective Efficient Integrated Pharmacy Benefits Program For The Military Health System Mhs Which Includes The Purchase Pharmaceutical Agents The Law And Implementing Regulation 32 Cfr Section 199 21 Describe The Process By Which The Dod Pharmacy And Therapeutics P Amp T Committee Will Consider The Relative Clinical Effectiveness And Relative Cost Effectiveness Of Pharmaceutical Agents In A Therapeutic Class In Recommending The Selection Of Agents For The Dod Uniform Formulary Uf And For Cost Sharing Purposes The Classification Of A Pharmaceutical Agent As Generic Formulary Basic Core Formulary Bcf Extended Core Formulary Ecf Or Non Formulary Nf Prior To The Scheduled P Amp T Committee Meeting A Request For Quotation Rfq For Pharmaceutical Agents Within Drug Classes Identified For Placement On The Uf Has Been Issued To Obtain Quotes From Industry The Defense Health Agency May Award Uniform Formulary Blanket Purchase Agreements Uf Bpa And The Uniform Formulary Additional Discount Program Agreements Uf Adp Based On The Uf Decision This Process Is Described In The Attached Rfq P Amp T Committee Meeting May 2020 The Following Drug Classes Subclass And Newly Approved Agents Will Be Reviewed Oncological Agents Sub Class N A Ayvakit Antipsychotic Agents Sub Class Atypical Caplyta Antihemophilic Factors Sub Class N A Esperoct Migraine Agents Sub Class N A Ubrelvy Migraine Agents Sub Class Second Generation Ubrelvy Anticonvulsants Antimania Agents Sub Class N A Valtoco Rfq The Rfq Including Uf Bpa And Uf Adp Appendices Are Attached Herein Pre Proposal Teleconference Is On February 12 2020 Details Are Stated In Part 2 5 Clinical Questions In Part 3 4 Shall Be Submitted Via E Mail To The Rfq Point Of Contact Stated In Part 2 3 No Later Than The Date Stated In Part 2 4 Pocs Part 2 3 Of The Rfq Update As Of 4 16 2020 Your Company Has Submitted A Price Concession In Support Of The 2020 May P Amp T Meeting As A Result Of The Covid 19 Pandemic We Will Be Adjusting Our 2020 May P Amp T Meeting At This Time We Expect To Not Complete The Drug Class Reviews We Will Only Be Reviewing Newly Approved Drugs That Have Been Posted To The Health Mil Pandt Website We Will Be Reviewing The Drugs From A Cost Perspective With The Price Submitted For The Bpa And Or Adp Quote Manufacturers That Are Being Considered As Part Of The Newly Approved Drug Program Need Not Take Any Action The Bap And Director Dha Review Of The Newly Approved Drugs Is Expected To Proceed As Scheduled For This Part And Other Actions That Are Considered As Part Of The May 2020 P Amp T Meeting

Refer document

FileName	File Description
Global Tender Document	Tender Notice